Nivolumab Global Market Report 2024

Description

“Nivolumab Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on nivolumab market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nivolumab? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The nivolumab market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Type: Injection 4mL; Injection 10mL
2) By Route Of Administration: Intravenous; Other Routes Of Administration
3) By Application: Melanoma; Non-small Cell Lung Cancer (NSCLC); Malignant Pleural Mesothelioma; Classical Hodgkin Lymphoma (CHL); Squamous Cell Carcinoma Of The Head And Neck (SCCHN); Renal Cell Carcinoma (RCC); Other Applications
4) By End-User: Clinic; Hospital; Other End-Users
Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Nivolumab is an immunoglobulin G4 (IgG4) fully human antibody that targets programmed cell death protein 1 (PD1). It is approved at a dosage of 3 mg/kg for the treatment of metastatic or unresectable melanoma, metastatic non-small cell lung cancer following platinum-based chemotherapy, and metastatic renal cell carcinoma in the second-line setting. Nivolumab is a targeted therapy medication employed in the management and treatment of various types of cancer, and it operates by enhancing the immune system's response to cancer cells.

Nivolumab is available in two main formulations such as an injection of 4 mL and an injection of 10 mL. The 40 mg/4 mL (10 mg/mL) solution of nivolumab is provided in single-use vials. This formulation is utilized in the treatment of melanoma, non-small cell lung cancer (NSCLC), and Hodgkin lymphoma. It is administered via intravenous and other routes for the treatment of conditions such as melanoma, NSCLC, malignant pleural mesothelioma, classical Hodgkin lymphoma (CHL), squamous cell carcinoma of the head and neck (SCCHN), renal cell carcinoma (RCC), and other cancer types. Nivolumab is used in clinical settings, hospitals, and other healthcare facilities for cancer treatment.

The nivolumab market research report is one of a series of new reports from The Business Research Company that provides nivolumab market statistics, including nivolumab industry global market size, regional shares, competitors with a nivolumab market share, detailed nivolumab market segments, market trends and opportunities and any further data you may need to thrive in the nivolumab industry. This nivolumab market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The nivolumab market size has grown rapidly in recent years. It will grow from $1.47 billion in 2023 to $1.69 billion in 2024 at a compound annual growth rate (CAGR) of 15.1%. The growth in the historic period can be attributed to immunotherapy advancements, increased incidence of cancer, clinical trial success, regulatory approvals.

The nivolumab market size is expected to see rapid growth in the next few years. It will grow to $2.81 billion in 2028 at a compound annual growth rate (CAGR) of 13.6%. The growth in the forecast period can be attributed to personalized medicine, emerging indications, global access to cancer care, advancements in combination therapies. Major trends in the forecast period include biomarker-driven treatment, neoantigen vaccines, enhanced immunotherapy regimens, long-term follow-up studies.

The growth of the nivolumab market is set to be significantly propelled by the increasing prevalence of cancer. Cancer encompasses a broad spectrum of diseases that can manifest in nearly any organ or tissue within the body. It is characterized by the uncontrolled proliferation of abnormal cells, which can breach their usual boundaries and have the potential to metastasize to other organs or infiltrate neighboring tissues. Nivolumab, a key player in cancer treatment, functions by preventing cancer cells from suppressing the immune system, thereby enabling the immune system to identify, target, and eliminate these malignant cells. As an illustrative instance, the American Cancer Society Inc., a non-profit health organization based in the United States, predicts that in 2023, there will be a staggering 1.9 million new cancer cases diagnosed in the U.S., marking an increase compared to the over 1.8 million cases identified in 2020. Consequently, the burgeoning prevalence of cancer serves as a robust driving force behind the expansion of the nivolumab market.

The increasing incidence of non-small cell lung cancer (NSCLC) is poised to be a prominent driver for the Nivolumab market's growth in the foreseeable future. NSCLC, a prevalent form of lung cancer originating in the epithelial cells of the lungs, is a major area of focus for Nivolumab. The drug has garnered approval for the treatment of advanced non-small cell lung cancer (NSCLC) owing to its proven efficacy in addressing this specific condition. Notably, data from the American Society of Clinical Oncology reveals that an estimated 238,340 individuals (comprising 117,550 men and 120,790 women) are anticipated to receive a lung cancer diagnosis in the United States in March 2023. Among these cases, NSCLC is the predominant subtype, representing approximately 81% of all lung cancer diagnoses. Consequently, the increased incidence of non-small cell lung cancer (NSCLC) stands as a formidable growth driver for the Nivolumab market.

The primary hurdle constraining market growth during the forecast period is the potential immune-related adverse events (IR-AEs) associated with Nivolumab usage. Nivolumab, known as an immune checkpoint inhibitor, has emerged as an innovative therapeutic option for cancer treatment. However, it is accompanied by several IR-AEs, including thyroid complications, colitis, pneumonitis, and, though rare, conditions such as type 1 diabetes, Guillain-Barre syndrome, and myasthenia gravis. The elevated incidence of IR-AEs linked to Nivolumab administration raises concerns regarding their potential increase as Nivolumab usage expands. For instance, in July 2021, the US-based pharmaceutical company Bristol-Myers Squibb made the challenging decision to voluntarily withdraw Opdivo (nivolumab) from the U.S. market as a monotherapy for individuals with hepatocellular carcinoma (HCC) who had previously received sorafenib treatment. Thus, the limiting factor influencing the Nivolumab market's growth is the possible immune-related adverse events associated with its utilization.

Prominent companies operating within the Nivolumab market are placing a significant emphasis on the development of innovative drugs aimed at enhancing patient care and sustaining their market positions. The creation of novel drugs holds the potential to improve treatment outcomes for patients grappling with various medical conditions. As an illustration, in May 2022, Bristol-Myers Squibb Co., a US-based pharmaceutical company primarily dedicated to therapeutic endeavors encompassing cancer, cardiovascular health, immunology, and fibrotic conditions, disclosed the FDA's approval of two Nivolumab-based regimens. These regimens included Nivolumab in combination with fluoropyrimidine and platinum-containing chemotherapy and Nivolumab paired with Yervoy (ipilimumab), for the first-line treatment of adult patients dealing with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC), regardless of PD-L1 status.

In November 2022, Lyvgen Biopharma Co. Ltd., a China-based biotechnology firm specializing in cancer treatment, entered into a collaborative partnership with Bristol-Myers Squibb Co. The collaboration's focal point is the assessment of LVGN7409 in conjunction with Nivolumab, targeting patients with non-small cell lung cancer. This combination therapy concurrently addresses the co-stimulatory checkpoint CD40 and the co-inhibitory checkpoint PD-1. This multifaceted approach is envisioned to enhance the effectiveness of immunotherapy for patients confronting diseases that exhibit resistance or refractoriness. Bristol-Myers Squibb Co. is a US-based pharmaceutical company with a primary focus on therapeutic domains spanning cancer, cardiovascular health, immunology, and fibrotic disorders, inclusive of pioneering developments in Nivolumab.

Major players in the nivolumab market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ono Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Nippon Kayaku Co. Ltd., Luye Pharma AG, Genentech Inc., Taiho Pharmaceutical Co. Ltd., SymBio Pharmaceuticals Ltd., Xbrane Biopharma AB, NeuClone Therapeutics Inc.

North America was the largest region in the nivolumab market in 2023. The regions covered in nivolumab report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the nivolumab market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nivolumab market consists of sales of opdivo, nivolumab injection, generic Nivolumab. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r12358

1. Executive Summary

2. Nivolumab Market Characteristics

3. Nivolumab Market Trends And Strategies

4. Nivolumab Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Nivolumab Market Size and Growth

5.1. Global Nivolumab Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Nivolumab Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Nivolumab Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Nivolumab Market Segmentation

6.1. Global Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Injection 4mL
Injection 10mL
6.2. Global Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Intravenous
Other Routes Of Administration
6.3. Global Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Melanoma
Non-small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Classical Hodgkin Lymphoma (CHL)
Squamous Cell Carcinoma Of The Head And Neck (SCCHN)
Renal Cell Carcinoma (RCC)
Other Applications
6.4. Global Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Clinic
Hospital
Other End-Users

7. Nivolumab Market Regional And Country Analysis

7.1. Global Nivolumab Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Nivolumab Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Nivolumab Market

8.1. Asia-Pacific Nivolumab Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Nivolumab Market

9.1. China Nivolumab Market Overview
9.2. China Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Nivolumab Market

10.1. India Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Nivolumab Market

11.1. Japan Nivolumab Market Overview
11.2. Japan Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Nivolumab Market

12.1. Australia Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Nivolumab Market

13.1. Indonesia Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Nivolumab Market

14.1. South Korea Nivolumab Market Overview
14.2. South Korea Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Nivolumab Market

15.1. Western Europe Nivolumab Market Overview
15.2. Western Europe Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Nivolumab Market

16.1. UK Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Nivolumab Market

17.1. Germany Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Nivolumab Market

18.1. France Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Nivolumab Market

19.1. Italy Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Nivolumab Market

20.1. Spain Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Nivolumab Market

21.1. Eastern Europe Nivolumab Market Overview
21.2. Eastern Europe Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Nivolumab Market

22.1. Russia Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Nivolumab Market

23.1. North America Nivolumab Market Overview
23.2. North America Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Nivolumab Market

24.1. USA Nivolumab Market Overview
24.2. USA Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Nivolumab Market

25.1. Canada Nivolumab Market Overview
25.2. Canada Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Nivolumab Market

26.1. South America Nivolumab Market Overview
26.2. South America Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Nivolumab Market

27.1. Brazil Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Nivolumab Market

28.1. Middle East Nivolumab Market Overview
28.2. Middle East Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Nivolumab Market

29.1. Africa Nivolumab Market Overview
29.2. Africa Nivolumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Nivolumab Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Nivolumab Market Competitive Landscape And Company Profiles

30.1. Nivolumab Market Competitive Landscape
30.2. Nivolumab Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Johnson & Johnson Services Inc.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. F. Hoffmann-La Roche Ltd.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Merck & Co. Inc.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. AbbVie Inc.
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Nivolumab Market Other Major And Innovative Companies

31.1. Novartis AG
31.2. Sanofi S.A.
31.3. Bristol-Myers Squibb Company
31.4. AstraZeneca plc
31.5. GlaxoSmithKline plc
31.6. Takeda Pharmaceutical Company Limited
31.7. Eli Lilly and Company
31.8. Amgen Inc.
31.9. Regeneron Pharmaceuticals Inc.
31.10. Astellas Pharma Inc.
31.11. Chugai Pharmaceutical Co. Ltd.
31.12. Daiichi Sankyo Company Limited
31.13. Eisai Co. Ltd.
31.14. Ono Pharmaceutical Co. Ltd.
31.15. Kyowa Kirin Co. Ltd.

32. Global Nivolumab Market Competitive Benchmarking

33. Global Nivolumab Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Nivolumab Market

35. Nivolumab Market Future Outlook and Potential Analysis

35.1 Nivolumab Market In 2028 - Countries Offering Most New Opportunities
35.2 Nivolumab Market In 2028 - Segments Offering Most New Opportunities
35.3 Nivolumab Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer